Download PDF
Semin Thromb Hemost 2010; 36(1): 071-081
DOI: 10.1055/s-0030-1248726
© Thieme Medical Publishers

Von Willebrand Factor, ADAMTS-13, and Thrombotic Thrombocytopenic Purpura

Zhou Zhou1 , Trung C. Nguyen1 , 2 , Prasenjit Guchhait1 , Jing-fei Dong1
  • 1Department of Medicine, Thrombosis Division, Section of Cardiovascular Science Research, Baylor College of Medicine, Houston, Texas
  • 2Department of Pediatrics, Section of Critical Care, Baylor College of Medicine, Houston, Texas
Further Information

Publication History

Publication Date:
13 April 2010 (online)

    Permissions and Reprints

ABSTRACT

For a disease with <80 years of history, clinical and basic research into thrombotic thrombocytopenic purpura (TTP) has been significantly accelerated since the identification of unusually large von Willebrand factor (VWF) multimers and deficiency of ADAMTS-13 (A Disintegrin And Metalloproteinase with Thrombospondin-1-like domains) as the potential cause. The VWF-cleaving metalloprotease ADAMTS-13 has since been extensively characterized and its biological action tested in vitro and in vivo. There have also been considerable efforts to understand the interaction between ADAMTS-13 and its substrate VWF, as well as its biological regulation. This review focuses on recent advances in our understanding of the biology of VWF cleavage by ADAMTS-13 and how this newly gained knowledge will eventually help the clinical management of patients with TTP. This review also discusses the potential for ADAMTS-13 as a therapeutic drug for thrombotic conditions other than TTP.

KEYWORDS

von Willebrand factor - ADAMTS-13 - fluid shear stress - thrombotic thrombocytopenic purpura - TTP

REFERENCES

  • 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc N Y Pathol Soc. 1924;  24 21
    PubMedGoogle Scholar
  • 2 Amorosi E L, Ultamann J E. Thrombocytopenic purpura: report of 16 cases and review of the literature.  Medicine. 1966;  45 139-159
    CrossrefPubMedGoogle Scholar
  • 3 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307(23) 1432-1435
    CrossrefPubMedGoogle Scholar
  • 4 Moake J L, Turner N A, Stathopoulos N A, Nolasco L H, Hellums J D. Involvement of large plasma von Willebrand factor (VWF) multimers and unusually large VWF forms derived from endothelial cells in shear stress-induced platelet aggregation.  J Clin Invest. 1986;  78(6) 1456-1461
    CrossrefPubMedGoogle Scholar
  • 5 Moake J L, Turner N A, Stathopoulos N A, Nolasco L, Hellums J D. Shear-induced platelet aggregation can be mediated by VWF released from platelets, as well as by exogenous large or unusually large VWF multimers, requires adenosine diphosphate, and is resistant to aspirin.  Blood. 1988;  71(5) 1366-1374
    PubMedGoogle Scholar
  • 6 Arya M, Anvari B, Romo G M et al.. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers.  Blood. 2002;  99(11) 3971-3977
    CrossrefPubMedGoogle Scholar
  • 7 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood. 1996;  87(10) 4223-4234
    CrossrefPubMedGoogle Scholar
  • 8 Tsai H M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.  Blood. 1996;  87(10) 4235-4244
    CrossrefPubMedGoogle Scholar
  • 9 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.  Blood. 2001;  98(6) 1662-1666
    CrossrefPubMedGoogle Scholar
  • 10 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413(6855) 488-494
    CrossrefPubMedGoogle Scholar
  • 11 Zheng X, Chung D, Takayama T K, Majerus E M, Sadler J E, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.  J Biol Chem. 2001;  276(44) 41059-41063
    CrossrefPubMedGoogle Scholar
  • 12 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.  Blood. 1998;  91(8) 2839-2846
    PubMedGoogle Scholar
  • 13 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339(22) 1585-1594
    CrossrefPubMedGoogle Scholar
  • 14 Scheiflinger F, Knöbl P, Trattner B et al.. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.  Blood. 2003;  102(9) 3241-3243
    CrossrefPubMedGoogle Scholar
  • 15 Weibel E R, Palade G E. New cytoplasmic components in arterial endothelia.  J Cell Biol. 1964;  23 101-112
    CrossrefPubMedGoogle Scholar
  • 16 Bowie E J, Solberg Jr L A, Fass D N et al.. Transplantation of normal bone marrow into a pig with severe von Willebrand’s disease.  J Clin Invest. 1986;  78(1) 26-30
    CrossrefPubMedGoogle Scholar
  • 17 Ginsburg D, Handin R I, Bonthron D T et al.. Human von Willebrand factor (VWF): isolation of complementary DNA (cDNA) clones and chromosomal localization.  Science. 1985;  228(4706) 1401-1406
    CrossrefPubMedGoogle Scholar
  • 18 Wagner D D, Marder V J. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization.  J Cell Biol. 1984;  99(6) 2123-2130
    CrossrefPubMedGoogle Scholar
  • 19 Wagner D D, Lawrence S O, Ohlsson-Wilhelm B M, Fay P J, Marder V J. Topology and order of formation of interchain disulfide bonds in von Willebrand factor.  Blood. 1987;  69(1) 27-32
    PubMedGoogle Scholar
  • 20 Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik J A, Pannekoek H. Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids.  J Cell Biol. 1991;  113(1) 195-205
    CrossrefPubMedGoogle Scholar
  • 21 Katsumi A, Tuley E A, Bodó I, Sadler J E. Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor.  J Biol Chem. 2000;  275(33) 25585-25594
    CrossrefPubMedGoogle Scholar
  • 22 Purvis A R, Gross J, Dang L T et al.. Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi.  Proc Natl Acad Sci U S A. 2007;  104(40) 15647-15652
    CrossrefPubMedGoogle Scholar
  • 23 Wagner D D, Fay P J, Sporn L A, Sinha S, Lawrence S O, Marder V J. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells.  Proc Natl Acad Sci U S A. 1987;  84(7) 1955-1959
    CrossrefPubMedGoogle Scholar
  • 24 Verweij C L, Hart M, Pannekoek H. Expression of variant von Willebrand factor (VWF) cDNA in heterologous cells: requirement of the pro-polypeptide in VWF multimer formation.  EMBO J. 1987;  6(10) 2885-2890
    PubMedGoogle Scholar
  • 25 Wise R J, Pittman D D, Handin R I, Kaufman R J, Orkin S H. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers.  Cell. 1988;  52(2) 229-236
    CrossrefPubMedGoogle Scholar
  • 26 Sporn L A, Marder V J, Wagner D D. Inducible secretion of large, biologically potent von Willebrand factor multimers.  Cell. 1986;  46(2) 185-190
    CrossrefPubMedGoogle Scholar
  • 27 Mannucci P M. Platelet von Willebrand factor in inherited and acquired bleeding disorders.  Proc Natl Acad Sci U S A. 1995;  92(7) 2428-2432
    CrossrefPubMedGoogle Scholar
  • 28 Huang R H, Wang Y, Roth R et al.. Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor.  Proc Natl Acad Sci U S A. 2008;  105(2) 482-487
    CrossrefPubMedGoogle Scholar
  • 29 Berriman J A, Li S, Hewlett L J et al.. Structural organization of Weibel-Palade bodies revealed by cryo-EM of vitrified endothelial cells.  Proc Natl Acad Sci U S A. 2009;  106(41) 17407-17412
    CrossrefPubMedGoogle Scholar
  • 30 Michaux G, Abbitt K B, Collinson L M, Haberichter S L, Norman K E, Cutler D F. The physiological function of von Willebrand’s factor depends on its tubular storage in endothelial Weibel-Palade bodies.  Dev Cell. 2006;  10(2) 223-232
    CrossrefPubMedGoogle Scholar
  • 31 Schorer A E, Moldow C F, Rick M E. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells.  Br J Haematol. 1987;  67(2) 193-197
    CrossrefPubMedGoogle Scholar
  • 32 Paleolog E M, Crossman D C, McVey J H, Pearson J D. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells.  Blood. 1990;  75(3) 688-695
    PubMedGoogle Scholar
  • 33 Padilla A, Moake J L, Bernardo A et al.. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface.  Blood. 2004;  103(6) 2150-2156
    CrossrefPubMedGoogle Scholar
  • 34 Huang J, Roth R, Heuser J E, Sadler J E. Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress.  Blood. 2009;  113(7) 1589-1597
    CrossrefPubMedGoogle Scholar
  • 35 Chauhan A K, Goerge T, Schneider S W, Wagner D D. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin.  J Thromb Haemost. 2007;  5(3) 583-589
    CrossrefPubMedGoogle Scholar
  • 36 Dong J F, Moake J L, Nolasco L et al.. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.  Blood. 2002;  100(12) 4033-4039
    CrossrefPubMedGoogle Scholar
  • 37 Bernardo A, Ball C, Nolasco L, Choi H, Moake J L, Dong J F. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress.  J Thromb Haemost. 2005;  3(3) 562-570
    CrossrefPubMedGoogle Scholar
  • 38 Groot E, Fijnheer R, Sebastian S A, de Groot P G, Lenting P J. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission.  J Thromb Haemost. 2009;  7(6) 962-969
    CrossrefPubMedGoogle Scholar
  • 39 Martin C, Morales L D, Cruz M A. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha.  J Thromb Haemost. 2007;  5(7) 1363-1370
    CrossrefPubMedGoogle Scholar
  • 40 Siedlecki C A, Lestini B J, Kottke-Marchant K K, Eppell S J, Wilson D L, Marchant R E. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.  Blood. 1996;  88(8) 2939-2950
    PubMedGoogle Scholar
  • 41 Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension.  Blood. 2003;  101(7) 2637-2645
    CrossrefPubMedGoogle Scholar
  • 42 Schneider S W, Nuschele S, Wixforth A et al.. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers.  Proc Natl Acad Sci U S A. 2007;  104(19) 7899-7903
    CrossrefPubMedGoogle Scholar
  • 43 Choi H, Aboulfatova K, Pownall H J, Cook R, Dong J F. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor.  J Biol Chem. 2007;  282(49) 35604-35611
    CrossrefPubMedGoogle Scholar
  • 44 Li Y, Choi H, Zhou Z et al.. Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions.  J Thromb Haemost. 2008;  6(7) 1135-1143
    CrossrefPubMedGoogle Scholar
  • 45 Xie L, Chesterman C N, Hogg P J. Reduction of von Willebrand factor by endothelial cells.  Thromb Haemost. 2000;  84(3) 506-513
    PubMedGoogle Scholar
  • 46 Xie L, Chesterman C N, Hogg P J. Control of von Willebrand factor multimer size by thrombospondin-1.  J Exp Med. 2001;  193(12) 1341-1349
    CrossrefPubMedGoogle Scholar
  • 47 Pimanda J E, Annis D S, Raftery M, Mosher D F, Chesterman C N, Hogg P J. The von Willebrand factor-reducing activity of thrombospondin-1 is located in the calcium-binding/C-terminal sequence and requires a free thiol at position 974.  Blood. 2002;  100(8) 2832-2838
    CrossrefPubMedGoogle Scholar
  • 48 Chen J, Fu X, Wang Y et al.. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13.  Blood. 2009;  , October 7 (Epub ahead of print)
    CrossrefPubMedGoogle Scholar
  • 49 Porter S, Clark I M, Kevorkian L, Edwards D R. The ADAMTS metalloproteinases.  Biochem J. 2005;  386(Pt 1) 15-27
    CrossrefPubMedGoogle Scholar
  • 50 Anderson P J, Kokame K, Sadler J E. Zinc and calcium ions cooperatively modulate ADAMTS13 activity.  J Biol Chem. 2006;  281(2) 850-857
    CrossrefPubMedGoogle Scholar
  • 51 Gardner M D, Chion C K, de Groot R, Shah A, Crawley J T, Lane D A. A functional calcium-binding site in the metalloprotease domain of ADAMTS13.  Blood. 2009;  113(5) 1149-1157
    CrossrefPubMedGoogle Scholar
  • 52 Mannucci P M, Canciani M T, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.  Blood. 2001;  98(9) 2730-2735
    CrossrefPubMedGoogle Scholar
  • 53 Tsai H M, Sarode R, Downes K A. Ultralarge von Willebrand factor multimers and normal ADAMTS13 activity in the umbilical cord blood.  Thromb Res. 2002;  108(2–3) 121-125
    CrossrefPubMedGoogle Scholar
  • 54 Uemura M, Tatsumi K, Matsumoto M et al.. Localization of ADAMTS13 to the stellate cells of human liver.  Blood. 2005;  106(3) 922-924
    CrossrefPubMedGoogle Scholar
  • 55 Zhou W, Inada M, Lee T P et al.. ADAMTS13 is expressed in hepatic stellate cells.  Lab Invest. 2005;  85(6) 780-788
    CrossrefPubMedGoogle Scholar
  • 56 Suzuki M, Murata M, Matsubara Y et al.. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets.  Biochem Biophys Res Commun. 2004;  313(1) 212-216
    CrossrefPubMedGoogle Scholar
  • 57 Liu L, Choi H, Bernardo A et al.. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13.  J Thromb Haemost. 2005;  3(11) 2536-2544
    CrossrefPubMedGoogle Scholar
  • 58 Turner N, Nolasco L, Tao Z, Dong J F, Moake J. Human endothelial cells synthesize and release ADAMTS-13.  J Thromb Haemost. 2006;  4(6) 1396-1404
    CrossrefPubMedGoogle Scholar
  • 59 Davis A K, Makar R S, Stowell C P, Kuter D J, Dzik W H. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13.  Transfusion. 2009;  49(2) 206-213
    CrossrefPubMedGoogle Scholar
  • 60 Vomund A N, Majerus E M. ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor.  J Biol Chem. 2009;  284(45) 30925-30932
    CrossrefPubMedGoogle Scholar
  • 61 Turner N A, Nolasco L, Ruggeri Z M, Moake J L. Endothelial cell ADAMTS-13 and VWF: production, release and VWF string cleavage.  Blood. 2009;  114(24) 5102-5111
    CrossrefPubMedGoogle Scholar
  • 62 Shang D, Zheng X W, Niiya M, Zheng X L. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts.  Blood. 2006;  108(7) 2207-2215
    CrossrefPubMedGoogle Scholar
  • 63 Zhou Z, Jing H, Tao Z et al.. Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13.  Thromb Res. 2009;  124(3) 323-327
    CrossrefPubMedGoogle Scholar
  • 64 Ricketts L M, Dlugosz M, Luther K B, Haltiwanger R S, Majerus E M. O-fucosylation is required for ADAMTS13 secretion.  J Biol Chem. 2007;  282(23) 17014-17023
    CrossrefPubMedGoogle Scholar
  • 65 Zhou W, Tsai H M. N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity.  Blood. 2009;  113(4) 929-935
    CrossrefPubMedGoogle Scholar
  • 66 Cao W J, Niiya M, Zheng X W, Shang D Z, Zheng X L. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells.  J Thromb Haemost. 2008;  6(7) 1233-1235
    CrossrefPubMedGoogle Scholar
  • 67 Nguyen T C, Liu A, Liu L et al.. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis.  Haemtologica. 2007;  92 121-124
    CrossrefPubMedGoogle Scholar
  • 68 Kremer Hovinga J A, Zeerleder S, Kessler P et al.. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock.  J Thromb Haemost. 2007;  5(11) 2284-2290
    CrossrefPubMedGoogle Scholar
  • 69 Zheng X, Nishio K, Majerus E M, Sadler J E. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.  J Biol Chem. 2003;  278(32) 30136-30141
    CrossrefPubMedGoogle Scholar
  • 70 Majerus E M, Anderson P J, Sadler J E. Binding of ADAMTS13 to von Willebrand factor.  J Biol Chem. 2005;  280(23) 21773-21778
    CrossrefPubMedGoogle Scholar
  • 71 Zhou W, Dong L, Ginsburg D, Bouhassira E E, Tsai H M. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?.  J Biol Chem. 2005;  280(48) 39934-39941
    CrossrefPubMedGoogle Scholar
  • 72 Feys H B, Anderson P J, Vanhoorelbeke K, Majerus E M, Sadler J E. Multi-step binding of ADAMTS13 to VWF.  J Thromb Haemost. 2009;  7(12) 2088-2095
    CrossrefPubMedGoogle Scholar
  • 73 Soejima K, Matsumoto M, Kokame K et al.. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.  Blood. 2003;  102(9) 3232-3237
    CrossrefPubMedGoogle Scholar
  • 74 Ai J, Smith P, Wang S, Zhang P, Zheng X L. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.  J Biol Chem. 2005;  280(33) 29428-29434
    CrossrefPubMedGoogle Scholar
  • 75 Gao W, Anderson P J, Majerus E M, Tuley E A, Sadler J E. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease.  Proc Natl Acad Sci U S A. 2006;  103(50) 19099-19104
    CrossrefPubMedGoogle Scholar
  • 76 de Groot R, Bardhan A, Ramroop N, Lane D A, Crawley J T. Essential role of the disintegrin-like domain in ADAMTS13 function.  Blood. 2009;  113(22) 5609-5616
    PubMedGoogle Scholar
  • 77 Zhang P, Pan W, Rux A H, Sachais B S, Zheng X L. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow.  Blood. 2007;  110(6) 1887-1894
    CrossrefPubMedGoogle Scholar
  • 78 Tao Z, Peng Y, Nolasco L et al.. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions.  Blood. 2005;  106(13) 4139-4145
    CrossrefPubMedGoogle Scholar
  • 79 Tao Z, Wang Y, Choi H et al.. Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow.  Blood. 2005;  106(1) 141-143
    CrossrefPubMedGoogle Scholar
  • 80 Akiyama M, Takeda S, Kokame K, Takagi J, Miyata T. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor.  Proc Natl Acad Sci U S A. 2009;  106(46) 19274-19279
    CrossrefPubMedGoogle Scholar
  • 81 Dong J F, Moake J L, Bernardo A et al.. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor.  J Biol Chem. 2003;  278(32) 29633-29639
    CrossrefPubMedGoogle Scholar
  • 82 Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13.  Blood. 2004;  103(2) 607-612
    CrossrefPubMedGoogle Scholar
  • 83 Wu J J, Fujikawa K, McMullen B A, Chung D W. Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor.  Proc Natl Acad Sci U S A. 2006;  103(49) 18470-18474
    CrossrefPubMedGoogle Scholar
  • 84 Zanardelli S, Crawley J T, Chion C K, Lam J K, Preston R J, Lane D A. ADAMTS13 substrate recognition of von Willebrand factor A2 domain.  J Biol Chem. 2006;  281(3) 1555-1563
    CrossrefPubMedGoogle Scholar
  • 85 Jenkins P V, Pasi K J, Perkins S J. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand’s disease.  Blood. 1998;  91(6) 2032-2044
    PubMedGoogle Scholar
  • 86 Tsai H M, Sussman I I, Nagel R L. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma.  Blood. 1994;  83(8) 2171-2179
    CrossrefPubMedGoogle Scholar
  • 87 Tsai H M. Shear stress and von Willebrand factor in health and disease.  Semin Thromb Hemost. 2003;  29(5) 479-488
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Baldauf C, Schneppenheim R, Stacklies W, et al.. Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis.  J Thromb Haemost. 2009;  7(12) 2096-2105
    CrossrefPubMedGoogle Scholar
  • 89 Zhang X, Halvorsen K, Zhang C Z, Wong W P, Springer T A. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor.  Science. 2009;  324(5932) 1330-1334
    CrossrefPubMedGoogle Scholar
  • 90 Wu T, Lin J, Cruz M A, Dong J F, Zhu C. Force-induced cleavage of single VWF A1A2A3-tridomains by ADAMTS-13.  Blood. 2010;  115(2) 370-378
    CrossrefPubMedGoogle Scholar
  • 91 Nishio K, Anderson P J, Zheng X L, Sadler J E. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.  Proc Natl Acad Sci U S A. 2004;  101(29) 10578-10583
    CrossrefPubMedGoogle Scholar
  • 92 Shim K, Anderson P J, Tuley E A, Wiswall E, Sadler J E. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress.  Blood. 2008;  111(2) 651-657
    CrossrefPubMedGoogle Scholar
  • 93 Cao W, Krishnaswamy S, Camire R M, Lenting P J, Zheng X L. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13.  Proc Natl Acad Sci U S A. 2008;  105(21) 7416-7421
    CrossrefPubMedGoogle Scholar
  • 94 Zanardelli S, Chion A C, Groot E et al.. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF.  Blood. 2009;  114(13) 2819-2828
    CrossrefPubMedGoogle Scholar
  • 95 Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases.  Semin Thromb Hemost. 2007;  33(8) 787-797
    Article in Thieme ConnectPubMedGoogle Scholar
  • 96 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.  Blood. 1997;  89(9) 3097-3103
    PubMedGoogle Scholar
  • 97 Furlan M, Robles R, Galbusera M et al.. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339(22) 1578-1584
    CrossrefPubMedGoogle Scholar
  • 98 Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.  Thromb Haemost. 1999;  81(1) 8-13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 99 Kokame K, Matsumoto M, Soejima K et al.. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.  Proc Natl Acad Sci U S A. 2002;  99(18) 11902-11907
    CrossrefPubMedGoogle Scholar
  • 100 Antoine G, Zimmermann K, Plaimauer B et al.. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13.  Br J Haematol. 2003;  120(5) 821-824
    CrossrefPubMedGoogle Scholar
  • 101 Assink K, Schiphorst R, Allford S et al.. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency.  Kidney Int. 2003;  63(6) 1995-1999
    CrossrefPubMedGoogle Scholar
  • 102 Savasan S, Lee S K, Ginsburg D, Tsai H M. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity.  Blood. 2003;  101(11) 4449-4451
    CrossrefPubMedGoogle Scholar
  • 103 Schneppenheim R, Budde U, Oyen F et al.. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.  Blood. 2003;  101(5) 1845-1850
    CrossrefPubMedGoogle Scholar
  • 104 Matsumoto M, Kokame K, Soejima K et al.. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome.  Blood. 2004;  103(4) 1305-1310
    CrossrefPubMedGoogle Scholar
  • 105 Licht C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe B. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).  Kidney Int. 2004;  66(3) 955-958
    CrossrefPubMedGoogle Scholar
  • 106 Uchida T, Wada H, Mizutani M Research Project on Genetics of Thrombosis et al. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura.  Blood. 2004;  104(7) 2081-2083
    CrossrefPubMedGoogle Scholar
  • 107 Pimanda J E, Maekawa A, Wind T, Paxton J, Chesterman C N, Hogg P J. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13.  Blood. 2004;  103(2) 627-629
    CrossrefPubMedGoogle Scholar
  • 108 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.  Best Pract Res Clin Haematol. 2001;  14(2) 437-454
    CrossrefPubMedGoogle Scholar
  • 109 Tao Z, Anthony K, Peng Y et al.. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura.  J Thromb Haemost. 2006;  4(9) 1931-1935
    CrossrefPubMedGoogle Scholar
  • 110 Motto D G, Chauhan A K, Zhu G et al.. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.  J Clin Invest. 2005;  115(10) 2752-2761
    CrossrefPubMedGoogle Scholar
  • 111 Karmali M A, Steele B T, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.  Lancet. 1983;  1(8325) 619-620
    PubMedGoogle Scholar
  • 112 Nolasco L H, Turner N A, Bernardo A et al.. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.  Blood. 2005;  106(13) 4199-4209
    CrossrefPubMedGoogle Scholar
  • 113 Chauhan A K, Walsh M T, Zhu G, Ginsburg D, Wagner D D, Motto D G. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis.  Blood. 2008;  111(7) 3452-3457
    CrossrefPubMedGoogle Scholar
  • 114 Studt J D, Hovinga J A, Antoine G et al.. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin.  Blood. 2005;  105(2) 542-544
    CrossrefPubMedGoogle Scholar
  • 115 Donadelli R, Banterla F, Galbusera M International Registry of Recurrent and Familial HUS/TTP et al. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura.  Thromb Haemost. 2006;  96(4) 454-464
    Article in Thieme ConnectPubMedGoogle Scholar
  • 116 Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura.  Semin Hematol. 2004;  41(1) 34-40
    CrossrefPubMedGoogle Scholar
  • 117 Plaimauer B, Fuhrmann J, Mohr G et al.. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation.  Blood. 2006;  107(1) 118-125
    CrossrefPubMedGoogle Scholar
  • 118 Bongers T N, De Maat M P, Dippel D W, Uitterlinden A G, Leebeek F W. Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians.  J Thromb Haemost. 2005;  3(4) 805
    CrossrefPubMedGoogle Scholar
  • 119 Ruan C, Dai L, Su J, Wang Z, Ruan C. The frequency of P475S polymorphism in von Willebrand factor-cleaving protease in the Chinese population and its relevance to arterial thrombotic disorders.  Thromb Haemost. 2004;  91(6) 1257-1258
    PubMedGoogle Scholar
  • 120 Terrell D R, Williams L A, Vesely S K, Lämmle B, Hovinga J A, George J N. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency.  J Thromb Haemost. 2005;  3(7) 1432-1436
    CrossrefPubMedGoogle Scholar
  • 121 Egerman R S, Witlin A G, Friedman S A, Sibai B M. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in pregnancy: review of 11 cases.  Am J Obstet Gynecol. 1996;  175(4 Pt 1) 950-956
    CrossrefPubMedGoogle Scholar
  • 122 McCrae K R, Cines D B. Thrombotic microangiopathy during pregnancy.  Semin Hematol. 1997;  34(2) 148-158
    PubMedGoogle Scholar
  • 123 Gerth J, Schleussner E, Kentouche K, Busch M, Seifert M, Wolf G. Pregnancy-associated thrombotic thrombocytopenic purpura.  Thromb Haemost. 2009;  101(2) 248-251
    PubMedGoogle Scholar
  • 124 Rieger M, Mannucci P M, Kremer Hovinga J A et al.. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.  Blood. 2005;  106(4) 1262-1267
    CrossrefPubMedGoogle Scholar
  • 125 Austin S K, Starke R D, Lawrie A S, Cohen H, Machin S J, Mackie I J. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction.  Br J Haematol. 2008;  141(4) 536-544
    CrossrefPubMedGoogle Scholar
  • 126 Matsuyama T, Kuwana M, Matsumoto M, Isonishi A, Inokuma S, Fujimura Y. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.  Thromb Haemost. 2009;  102(2) 371-378
    PubMedGoogle Scholar
  • 127 Shimizu M, Nomura S, Ishii K et al.. The significance of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura complicated autoimmune hepatitis.  Thromb Haemost. 2009;  101(3) 599-600
    PubMedGoogle Scholar
  • 128 Kiki I, Gundogdu M, Albayrak B, Bilgiç Y. Thrombotic thrombocytopenic purpura associated with Brucella infection.  Am J Med Sci. 2008;  335(3) 230-232
    CrossrefPubMedGoogle Scholar
  • 129 Rossi F C, Angerami R N, de Paula E V et al.. A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection.  Transfusion. 2009;  , September 24 (Epub ahead of print)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 130 Yagita M, Uemura M, Nakamura T, Kunitomi A, Matsumoto M, Fujimura Y. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura.  J Hepatol. 2005;  42(3) 420-421
    CrossrefPubMedGoogle Scholar
  • 131 Uemura M, Fujimura Y, Matsumoto M et al.. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis.  Thromb Haemost. 2008;  99(6) 1019-1029
    Article in Thieme ConnectPubMedGoogle Scholar
  • 132 Bennett C L, Connors J M, Carwile J M et al.. Thrombotic thrombocytopenic purpura associated with clopidogrel.  N Engl J Med. 2000;  342(24) 1773-1777
    CrossrefPubMedGoogle Scholar
  • 133 Bennett C L, Kim B, Zakarija A SERF-TTP Research Group et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.  J Am Coll Cardiol. 2007;  50(12) 1138-1143
    CrossrefPubMedGoogle Scholar
  • 134 Zakarija A, Kwaan H C, Moake J L et al.. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989–2008).  Kidney Int Suppl. 2009;  112 S20-S24
    PubMedGoogle Scholar
  • 135 Vesely S K, George J N, Lämmle B et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102(1) 60-68
    CrossrefPubMedGoogle Scholar
  • 136 Shelat S G, Smith P, Ai J, Zheng X L. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.  J Thromb Haemost. 2006;  4(8) 1707-1717
    CrossrefPubMedGoogle Scholar
  • 137 Shelat S G, Ai J, Zheng X L. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.  Semin Thromb Hemost. 2005;  31(6) 659-672
    Article in Thieme ConnectPubMedGoogle Scholar
  • 138 Ferrari S, Mudde G C, Rieger M, Veyradier A, Kremer Hovinga J A, Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura.  J Thromb Haemost. 2009;  7(10) 1703-1710
    CrossrefPubMedGoogle Scholar
  • 139 Klaus C, Plaimauer B, Studt J D et al.. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.  Blood. 2004;  103(12) 4514-4519
    CrossrefPubMedGoogle Scholar
  • 140 Luken B M, Kaijen P H, Turenhout E A et al.. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura.  J Thromb Haemost. 2006;  4(11) 2355-2364
    CrossrefPubMedGoogle Scholar
  • 141 Luken B M, Turenhout E A, Kaijen P H et al.. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP.  Thromb Haemost. 2006;  96(3) 295-301
    PubMedGoogle Scholar
  • 142 Moake J L, Byrnes J J. Thrombotic microangiopathies associated with drugs and bone marrow transplantation.  Hematol Oncol Clin North Am. 1996;  10(2) 485-497
    CrossrefPubMedGoogle Scholar
  • 143 Elliott M A, Nichols Jr W L, Plumhoff E A et al.. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.  Mayo Clin Proc. 2003;  78(4) 421-430
    CrossrefPubMedGoogle Scholar
  • 144 Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Deficient activity of von Willebrand’s factor-cleaving protease in patients with disseminated malignancies.  Cancer Res. 1999;  59(9) 2244-2250
    PubMedGoogle Scholar
  • 145 Mannucci P M, Karimi M, Mosalaei A, Canciani M T, Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease).  Haematologica. 2003;  88(4) 454-458
    PubMedGoogle Scholar
  • 146 Medina P J, Sipols J M, George J N. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Curr Opin Hematol. 2001;  8(5) 286-293
    CrossrefPubMedGoogle Scholar
  • 147 Sugimoto T, Saigo K, Shin T et al.. Von Willebrand factor-cleaving protease activity remains at the intermediate level in thrombotic thrombocytopenic purpura.  Acta Haematol. 2005;  113(3) 198-203
    CrossrefPubMedGoogle Scholar
  • 148 Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy.  Semin Thromb Hemost. 2005;  31(6) 681-690
    Article in Thieme ConnectPubMedGoogle Scholar
  • 149 Bernardo A, Ball C, Nolasco L, Moake J F, Dong J F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow.  Blood. 2004;  104(1) 100-106
    CrossrefPubMedGoogle Scholar
  • 150 Crawley J T, Lane D A, Woodward M, Rumley A, Lowe G D. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack.  J Thromb Haemost. 2008;  6(4) 583-588
    CrossrefPubMedGoogle Scholar
  • 151 Fuchigami S, Kaikita K, Soejima K et al.. Changes in plasma von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina.  Thromb Res. 2008;  122(5) 618-623
    CrossrefPubMedGoogle Scholar
  • 152 Bongers T N, de Bruijne E L, Dippel D W et al.. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients.  Atherosclerosis. 2009;  207(1) 250-254
    CrossrefPubMedGoogle Scholar
  • 153 Gombos T, Makó V, Cervenak L et al.. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure.  Thromb Haemost. 2009;  102(3) 573-580
    PubMedGoogle Scholar
  • 154 Bongers T N, de Maat M P, van Goor M L et al.. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.  Stroke. 2006;  37(11) 2672-2677
    CrossrefPubMedGoogle Scholar
  • 155 Vergouwen M D, Bakhtiari K, van Geloven N, Vermeulen M, Roos Y B, Meijers J C. Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.  J Cereb Blood Flow Metab. 2009;  29(10) 1734-1741
    CrossrefPubMedGoogle Scholar
  • 156 Matsuyama T, Uemura M, Ishikawa M et al.. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.  Alcohol Clin Exp Res. 2007;  31(1, suppl) S27-S35
    CrossrefPubMedGoogle Scholar
  • 157 Uemura M, Fujimura Y, Matsuyama T et al.. Potential role of ADAMTS13 in the progression of alcoholic hepatitis.  Curr Drug Abuse Rev. 2008;  1(2) 188-196
    PubMedGoogle Scholar
  • 158 Morioka C, Uemura M, Matsuyama T et al.. Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis.  Scand J Gastroenterol. 2008;  43(11) 1387-1396
    CrossrefPubMedGoogle Scholar
  • 159 de Mast Q, Groot E, Lenting P J et al.. Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria.  J Infect Dis. 2007;  196(4) 622-628
    CrossrefPubMedGoogle Scholar
  • 160 de Mast Q, Groot E, Asih P B de MQ et al. ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria.  Am J Trop Med Hyg. 2009;  80(3) 492-498
    PubMedGoogle Scholar
  • 161 Larkin D, de Laat B, Jenkins P V et al.. Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition.  PLoS Pathog. 2009;  5(3) e1000349
    CrossrefPubMedGoogle Scholar
  • 162 Nguyen T C, Han Y Y, Kiss J E et al.. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.  Crit Care Med. 2008;  36(10) 2878-2887
    CrossrefPubMedGoogle Scholar
  • 163 Zhou Z, Han H, Cruz M A, López J A, Dong J F, Guchhait P. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease.  Thromb Haemost. 2009;  101(6) 1070-1077
    PubMedGoogle Scholar
  • 164 Chauhan A K, Motto D G, Lamb C B et al.. Systemic antithrombotic effects of ADAMTS13.  J Exp Med. 2006;  203(3) 767-776
    CrossrefPubMedGoogle Scholar
  • 165 Zhao B Q, Chauhan A K, Canault M et al.. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.  Blood. 2009;  114(15) 3329-3334
    CrossrefPubMedGoogle Scholar

Zhou ZhouM.D. Ph.D. 

Thrombosis Division, Section of Cardiovascular Research, Department of Medicine

Baylor College of Medicine, Houston, TX

Email: zz144319@bcm.tmc.edu